Clinical Trial Update: Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating whether atorvastatin can reduce cisplatin-induced hearing loss in individuals with head and neck cancer, and the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Hearing Loss

Drugs mentioned

• atorvastatin (atorvastatin)

Snippet

Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD) | Conditions: Hearing Loss, Head and Neck Cancer | Phase 2 | Status: RECRUITING